Diagnostic utility of P63 (AB-1) and (AB-4) tumor markers in the squamous cell carcinomas of head and neck

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 3, 2012, Pages 975-978

  Khan, Nauman Rauf ^a   Khan, Amna Nauman ^a   Bashir, Saira ^b   Khan, Ayyaz Ali ^c   Suleman, Bilquis A ^d   Chaudhry, Saima ^c  

^a Sharif Medical and Dental College   (Pakistan)

^b National Institute of Heart Diseases National University of Medical Sciences   (Pakistan)

^c Shaikh Zayed Post Graduate Medical Complex   (Pakistan)

^d UNIVERSITY OF LAHORE   (Pakistan)

Author keywords

Genotoxic stress; Head and neck cancer; Immunostaining; Oligomerization; P 63; Squamous cell carcinoma

Indexed keywords

CKAP4 PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL CYCLE CHECKPOINT; CHILD; FEMALE; GENETICS; HEAD AND NECK TUMOR; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PRESCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL CYCLE CHECKPOINTS; CHILD; CHILD, PRESCHOOL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84871673528     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.3.975     Document Type: Article

References (27)

1. Andrea T, Anette W (2001). Tumor markers in squamous cell carcinoma of the head and neck: clinical effectiveness and prognostic value. Eur Arch Otorhinolaryngol, 258, 83-8.
2. Bircan S, Candir O, Kapucoglu N, Baspinar S (2006). The expression of p63 in basal cell carcionomas and association with histological differentiation. J Cutan Pathol, 33, 293-8.
3. Buffa FM, Bentzen SM, Daley FM (2004). Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin Cancer Res, 10, 3745.
4. Chen YK, Hsue SS, Lin LM (2003). Immunohistochemical demonstration of p63 in DMBA-induced hamster buccal pouch squamous cell carcinogenesis. Oral Dis, 9, 235-40.
5. Chen YK, Huse SS, Lin LM (2003). Differential expression of p53, p63 and p73 proteins in human buccal squamous-cell carcinomas. Clin Otolaryngol, 28, 451-5.
6. Choi HR, Batsakis JG, Zhan F, et al (2002). Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Hum Pathol, 33, 158-64.
7. Coindre JM (2003). Immunohistochemistry in the diagnosis of soft tissue tumors. Histopathology, 43, 1-16.
8. Di Como CJ, Urist MJ, Babayan I, et al (2002). p63 expression profiles in human normal and tumor tissues. Clin Cancer Res, 8, 494-501.
9. Faridoni-laurens L, Bosq J, Janot F (2001). P73 expression in basal layers of head and neck squamous epithelium: a role in differentiation and carcinogenesis in concert with p53 and p63. Oncogene, 20, 5302-12.
10. Foschini MP, Gaiba A, Cocchi R (2004). Pattern of p63 expression in squamous cell carcinoma of the oral cavity. Virchows Arch, 444, 332-9.
11. Gath H, Brakenhoff R (1999). Minimal residual disease in head and neck cancer. Cancer Metastasis Rev, 18, 109-26.
12. Ivan D, Diwan AH, Prieto VG (2005). Expression of p63 in primary cutaneous adnexal neoplasms and adenocarcinoma metastatic to the skin. Mod Pathol, 18, 137-42.
13. Jimenez FJ, Grichnik JM, Buchanan MD, Clark RE (1995). Immunohistochemical techniques in Mohs micrographic surgery: their potential use in the detection of neoplastic cells masked by inflammation. J Am Acad Dermatol, 32, 89-94.
14. Kargi A, Gurel D, Tuna B (2007). The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. App Immunohistochemist Mol Morphol, 15, 415-20.
15. Kaufmann O, Fietze E, Mengs J, Dietel M (2001). Value of p63 and Cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol, 116, 823-30.
16. Koga F, Kawakami S, Fujii Y (2003). Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res, 9, 5501-7.
17. Kristiansen G, Fritzsche FR, Wassermann K, et al (2008). GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer, 99, 939-48.
18. Levrero M, De Laurenzi V, Costanzo A, et al. (1999). Structure, function and regulation of p63 and p73. Cell Death Differ, 6, 1146-53.
19. Moskaluk CA (2002). Standardization of Clinical Immunohistochemistry: why, how, and by whom? Am J Clin Pathol, 118, 669-71.
20. Muzio LL, Santarelli A (2005). p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma. Hum Pathol, 36, 187-94.
21. Muzio LL, Campisi G, Farina A, et al (2007). Effect of p63 expression on survival in oral squamous cell carcinoma. Cancer Invest, 25, 464-9.
22. Nylander K, Coates PJ, Hall PA (2000). Characterization of the expression pattern of p63 and np63 in benign and malignant oral epithelial lesions. Int J Cancer, 87, 368-72.
23. Pitiphat W, Diehl SR, Laskaris G, et al (2002). Factors associated with delay in the diagnosis of oral cancer. J Dent Res, 81, 192-7.
24. Rassam MB, Al-Bashir NN, Al-Salihi AR, et al (1995). Heat-stable alkaline phosphatase: A putative tumor marker of head and neck squamous cell carcinoma. Acta Oncol, 34, 49-52.
25. Sayan BS, Sayan AE, Yang AL et al (2007). Cleavage of the transactivation inhibitory domain of p63 by caspases enhances apoptosis. PNAS, 104, 10871-6.
26. Strong EW, Kasdorf H, Henk JM (1995). Squamous cell carcinoma of the head and neck. In: Prognostic factors in cancer. Eds. Hermanek P, Gospodarowicz MK, Henson DE, et al. Springer, Berlin Heidelberg New York pp 12-22.
27. Yang A, Kagdah M, Wang Y, et al (1998). p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell, 2, 305-16